AtriCure, Inc. (NASDAQ:ATRC) has been delivering revenue growth and improved profitability, but the bigger question for investors is whether the latest results had any underlying catalysts strong enough to support the long-term growth potential.
The company reported its Q2 FY26 earnings on July 23, delivering revenue of $153.6 million and an adjusted EPS of $0.18. With healthy growth and a step up in profitability, the company’s revenue and adjusted EPS exceeded the consensus estimates by $1.79 million and $0.16, respectively. This marks a solid 800% EPS beat.
Inside the Q2 Results
The highlight of the quarter was net income of $9 million, compared with a net loss of $6.2 million in Q2 of 2025. Thanks to the continued adoption in the pain management franchise, appendage management franchise, and open ablation franchise, the company delivered $27 million in adjusted EBITDA.
Copyright: nimon / 123RF Stock Photo
Gross margin increased to 77.2% in Q2 2026, up 270 basis points from the Q2 2025 level, primarily driven by product innovation, geographic mix, and efficiencies. The company’s US business was up 14% YoY, with worldwide revenue growing 13%.
While the appendage management franchise grew 14% in the quarter, driven by AtriClip FLEX-Mini and PRO-Mini products, pain management saw another fantastic quarter, delivering 27% worldwide growth. This was due to the adoption of CryoSphere MAX.
Management expects continued gross margin benefits in the second half, despite a small headwind from its new manufacturing facility, which is aimed at enhancing the current manufacturing capability and capacity.
Can AtriCure Keep Growing From Here
The key catalyst is post-operative AFib, the healthcare spending for which surpasses $2 billion annually. Through the BoxX-NoAF clinical study, AtriCure, Inc. (NASDAQ:ATRC) will be able to capitalize on this opportunity. The company is on track to enroll all 960 patients by the year-end, even ahead of its original plan.
The second most powerful catalyst is its LeAAPS clinical trial, which focuses on cardiac surgery patients without AFib. This will help broaden the company’s addressable market. Together, these two studies will provide AtriCure, Inc. (NASDAQ:ATRC) with complementary paths for label expansion in the cardiac surgery market.
The company is also engaged in increasing the adoption of the Encompass clamp. The new STS quality metric on concomitant AFib treatment is anticipated to enhance the adoption even further.
With that said, management sees $602 million-$610 million in revenue for the year. The company also raised its adjusted EBITDA guidance to nearly $85 million-$89 million and an EPS of roughly $0.05-$0.13 for the full-year 2026.
At its current price, ATRC appears reasonably valued. The company trades at a forward P/B of 2.95x, below the sector median of 3.47x. The valuation becomes even more compelling when we consider the company’s long-term potential.
Key Risks to Consider
As the company capitalizes on the billion-dollar opportunity, many big names are expected to compete. For instance, on June 29, Edwards Lifesciences Corporation (NYSE:EW) received FDA approval for its Ecliptis left atrial appendage exclusion system, which will directly compete with AtriCure’s AtriClip platform. Earlier, the company was facing competition from Medtronic plc (NYSE:MDT), as the latter rolled out the Penditure LAA exclusion system in November 2023.
However, analysts at Canaccord Genuity believe the launch will have minimal impact on the company’s AtriClip business, which remains well-positioned in the surgical left atrial appendage closure market. Similarly, Medtronic’s launch had little impact on the company’s product.
The company also experiences international softness, particularly in the U.K. and Germany. While this has the potential to weigh on future results, management is optimistic that Encompass adoption will offset the impact of CryoSphere probe losing reimbursement in that market.
Institutional Interest Supports Investment Thesis
According to Insider Monkey’s database, the hedge fund ownership dipped marginally to 27 funds in Q1 2026 from 28 in the previous quarter. The relatively small change suggests that institutional investors have largely maintained their exposure to the company amid its growth momentum. Several notable hedge funds maintain positions in ATRC, including Hood River Capital Management and Marshall Wace LLP.
Overall, the company is a compelling long-term investment case, driven by the growing adoption of the Encompass clamp and its potential to capitalize on the post-operative AFib opportunity. With management raising its adjusted EBITDA guidance and the stock trading below the sector median, ATRC appears reasonably valued relative to its growth potential. However, investors should continue to monitor the competitive landscape and international headwinds.
While we acknowledge the risk and potential of ATRC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATRC and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years
Disclosure: None. Follow Insider Monkey on Google News.
